Innovent Biologics, Inc.
1801
Rank in Stocks
#1161
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou,... Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
Share Price
$11.40
Market Cap
$19.88B
Change (1 day)
1.95%
Change (1 year)
1.94%
Country
CN
Trade Innovent Biologics, Inc. (1801)
Category
Healthcare
Revenue for Innovent Biologics, Inc. (1801)
Revenue in Jun 2026 TTM: $2.26B
According to Innovent Biologics, Inc. latest financial reports the company's current revenue (TTM) is $2.26B. In 2023 the company made a revenue of $876.74M an increase over the revenue in the year 2022 that was $660.55M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Innovent Biologics, Inc. from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $2.26B | 74.99% |
| 2024 | $1.29B | 47.23% |
| 2023 | $876.74M | 32.73% |
| 2022 | $660.55M | -1.67% |
| 2021 | $671.77M | 14.17% |
| 2020 | $588.40M | 291.13% |
| 2019 | $150.44M | 10,818.89% |
| 2018 | $1.38M | -51.65% |
| 2017 | $2.85M | -38.42% |
| 2016 | $4.63M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 458.89% |
US
|
|
| $2.23B | -1.36% |
US
|
|
| $15.74B | 597.02% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 166.57% |
NL
|
